Skip to contentO
Opus Genetics, Inc.
O
IRDOpus Genetics, Inc. Q3 2023 · 10-Q
Revenue$11.94M$11.94M— vs Q3 2022 Net Income$5.56M$5.56MN/M vs Q3 2022 EPS Diluted$0.25$0.25N/M vs Q3 2022 Operating Income$6,386,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Opus Genetics, Inc. · CIK 1228627 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin53.5%
Net margin46.6%
ended Sep 30, 2023 · filed Nov 13, 2023 · 44 d after period end